|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Catenacci DVT, Tebbutt NC, Davidenko I,
Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E,
Karaszewska B, Bondarenko I, et al: Rilotumumab plus epirubicin,
cisplatin, and capecitabine as first-line therapy in advanced
MET-positive gastric or gastro-oesophageal junction cancer
(RILOMET-1): A randomised, double-blind, placebo-controlled, phase
3 trial. Lancet Oncol. 18:1467–1482. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Iveson T, Donehower RC, Davidenko I,
Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas
A, Jiang Y, et al: Rilotumumab in combination with epirubicin,
cisplatin, and capecitabine as first-line treatment for gastric or
oesophagogastric junction adenocarcinoma: An open-label, dose
de-escalation phase 1b study and a double-blind, randomised phase 2
study. Lancet Oncol. 15:1007–1018. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peng L, Yang W, Zhang Z, Liu H and Hua Y:
Clinical features and prognosis analysis of 21 gastric cancer
patients with pathological complete response after neoadjuvant
chemotherapy. Zhonghua Wei Chang Wai Ke Za Zhi. 20:1168–1173.
2017.In Chinese. PubMed/NCBI
|
|
5
|
Polkowska-Pruszyńska B, Rawicz-Pruszyński
K, Ciseł B, Sitarz R, Polkowska G, Krupski W and Polkowski WP:
Liver metastases from gastric carcinoma: A Case report and review
of the literature. Curr Probl Cancer. 41:222–230. 2017. View Article : Google Scholar
|
|
6
|
Oltean S and Bates DO: Hallmarks of
alternative splicing in cancer. Oncogene. 33:5311–5318. 2014.
View Article : Google Scholar
|
|
7
|
Siegfried Z and Karni R: The role of
alternative splicing in cancer drug resistance. Curr Opin Genet
Dev. 48:16–21. 2018. View Article : Google Scholar
|
|
8
|
Wojtuszkiewicz A, Assaraf YG, Maas MJ,
Kaspers GJ, Jansen G and Cloos J: Pre-mRNA splicing in cancer: The
relevance in oncogenesis, treatment and drug resistance. Expert
Opin Drug Metab Toxicol. 11:673–689. 2015. View Article : Google Scholar
|
|
9
|
Dehm SM: mRNA splicing variants:
Exploiting modularity to outwit cancer therapy. Cancer Res.
73:5309–5314. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bonnal S, Vigevani L and Valcárcel J: The
spliceosome as a target of novel antitumour drugs. Nat Rev Drug
Discov. 11:847–859. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kole R, Krainer AR and Altman S: RNA
therapeutics: Beyond RNA interference and antisense
oligonucleotides. Nat Rev Drug Discov. 11:125–140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hua Y, Sahashi K, Rigo F, Hung G, Horev G,
Bennett CF and Krainer AR: Peripheral SMN restoration is essential
for long-term rescue of a severe spinal muscular atrophy mouse
model. Nature. 478:123–126. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Godfrey C, Desviat LR, Smedsrød B,
Piétri-Rouxel F, Denti MA, Disterer P, Lorain S, Nogales-Gadea G,
Sardone V, Anwar R, et al: Delivery is key: Lessons learnt from
developing splice-switching antisense therapies. EMBO Mol Med.
9:545–557. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gopisetty G and Thangarajan R: Mammalian
mitochondrial ribosomal small subunit (MRPS) genes: A putative role
in human disease. Gene. 589:27–35. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim HJ, Maiti P and Barrientos A:
Mitochondrial Ribosomes in Cancer. Semin Cancer Biol. 47:67–81.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu L, Luo C, Luo Y, Chen L, Liu Y, Wang
Y, Han J, Zhang Y, Wei N, Xie Z, et al: MRPL33 and its splicing
regulator hnRNPK are required for mitochondria function and
implicated in tumor progression. Oncogene. 37:86–94. 2018.
View Article : Google Scholar
|
|
17
|
Liu T, Sun H, Zhu D, Dong X, Liu F, Liang
X, Chen C, Shao B, Wang M, Wang Y, et al: TRA2A Promoted Paclitaxel
Resistance and Tumor Progression in Triple-Negative Breast Cancers
via Regulating Alternative Splicing. Mol Cancer Ther. 16:1377–1388.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Wang J, Yu J, Zhao Y, Dong Y, Fan Y,
Li N, Zhang Y and Wang Y: Knockdown of POLE2 expression suppresses
lung adenocarcinoma cell malignant phenotypes in vitro. Oncol Rep.
40:2477–2486. 2018.PubMed/NCBI
|
|
19
|
Chen S, Zhang L, Su Y and Zhang X:
Screening potential biomarkers for colorectal cancer based on
circular RNA chips. Oncol Rep. 39:2499–2512. 2018.PubMed/NCBI
|
|
20
|
Howe EA, Sinha R, Schlauch D and
Quackenbush J: RNA-Seq analysis in MeV. Bioinformatics.
27:3209–3210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun S, Wang Y, Wu Y, Gao Y, Li Q,
Abdulrahman AA, Liu XF, Ji GQ, Gao J, Li L, et al: Identification
of COL1A1 as an invasion related gene in malignant astrocytoma. Int
J Oncol. 53:2542–2554. 2018.PubMed/NCBI
|
|
22
|
Ge Y, Weygant N, Qu D, May R, Berry WL,
Yao J, Chandrakesan P, Zheng W, Zhao L, Zhao KL, et al: Alternative
splice variants of DCLK1 mark cancer stem cells, promote
self-renewal and drug-resistance, and can be targeted to inhibit
tumorigenesis in kidney cancer. Int J Cancer. 143:1162–1175. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wan L, Yu W, Shen E, Sun W, Liu Y, Kong J,
Wu Y, Han F, Zhang L, Yu T, et al: SRSF6-regulated alternative
splicing that promotes tumour progression offers a therapy target
for colorectal cancer. Gut. 68:118–129. 2019. View Article : Google Scholar
|
|
24
|
Smith LD, Leme de Calais F, Raponi M,
Mellone M, Buratti E, Blaydes JP and Baralle D: Novel
splice-switching oligonucleotide promotes BRCA1 aberrant splicing
and susceptibility to PARP inhibitor action. Int J Cancer.
140:1564–1570. 2017. View Article : Google Scholar
|
|
25
|
Le KQ, Prabhakar BS, Hong WJ and Li LC:
Alternative splicing as a biomarker and potential target for drug
discovery. Acta Pharmacol Sin. 36:1212–1218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Anderson GR, Wardell SE, Cakir M, Yip C,
Ahn YR, Ali M, Yllanes AP, Chao CA, McDonnell DP and Wood KC:
Dysregulation of mitochondrial dynamics proteins are a targetable
feature of human tumors. Nat Commun. 9:16772018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen A, Tiosano D, Guran T, Baris HN,
Bayram Y, Mory A, Shapiro-Kulnane L, Hodges CA, Akdemir ZC, Turan
S, et al: Mutations in the mitochondrial ribosomal protein MRPS22
lead to primary ovarian insufficiency. Hum Mol Genet. 27:1913–1926.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Richter U, Lahtinen T, Marttinen P,
Myöhänen M, Greco D, Cannino G, Jacobs HT, Lietzén N, Nyman TA and
Battersby BJ: A mitochondrial ribosomal and RNA decay pathway
blocks cell proliferation. Curr Biol. 23:535–541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hao C, Duan H, Li H, Wang H, Liu Y, Fan Y
and Zhang C: Knockdown of MRPL42 suppresses glioma cell
proliferation by inducing cell cycle arrest and apoptosis. Biosci
Rep. 38:BSR201714562018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bijur GN and Jope RS: Rapid accumulation
of Akt in mitochondria following phosphatidylinositol 3-kinase
activation. J Neurochem. 87:1427–1435. 2003. View Article : Google Scholar
|
|
31
|
Vivanco I, Chen ZC, Tanos B, Oldrini B,
Hsieh WY, Yannuzzi N, Campos C and Mellinghoff IK: A
kinase-independent function of AKT promotes cancer cell survival.
eLife. 3:e037512014. View Article : Google Scholar
|
|
32
|
Agarwal E, Brattain MG and Chowdhury S:
Cell survival and metastasis regulation by Akt signaling in
colorectal cancer. Cell Signal. 25:1711–1719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nath S and Mandal C, Chatterjee U and
Mandal C: Association of cytosolic sialidase Neu2 with plasma
membrane enhances Fas-mediated apoptosis by impairing
PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells. Cell
Death Dis. 9:2102018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Suyama K, Yao J, Liang H, Benard O, Loudig
OD, Amgalan D, McKimpson WM, Phillips GR, Segall J, Wang Y, et al:
An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site
Promotes Apoptosis and Suppresses Mammary Tumorigenesis. Cancer
Res. 78:103–114. 2018. View Article : Google Scholar
|
|
35
|
Li T, Zhao X, Mo Z, Huang W, Yan H, Ling Z
and Ye Y: Formononetin promotes cell cycle arrest via
downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer
cells. Cell Physiol Biochem. 34:1351–1358. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang H, Xu W, Li B, Zhang K, Wu Y, Xu H,
Wang J, Zhang J, Fan R and Wei J: Curcumin Promotes Cell Cycle
Arrest and Inhibits Survival of Human Renal Cancer Cells by
Negative Modulation of the PI3K/AKT Signaling Pathway. Cell Biochem
Biophys. 73:681–686. 2015. View Article : Google Scholar
|
|
37
|
Wei J and Wu J, Xu W, Nie H, Zhou R, Wang
R, Liu Y, Tang G and Wu J: Salvianolic acid B inhibits glycolysis
in oral squamous cell carcinoma via targeting PI3K/AKT/HIF-1α
signaling pathway. Cell Death Dis. 9:5992018. View Article : Google Scholar
|
|
38
|
Avanzato D, Pupo E, Ducano N, Isella C,
Bertalot G, Luise C, Pece S, Bruna A, Rueda OM, Caldas C, et al:
High USP6NL levels in breast cancer sustain chronic AKT
phosphorylation and GLUT1 stability fueling aerobic glycolysis.
Cancer Res. 78:3432–3444. 2018.PubMed/NCBI
|
|
39
|
Haas B, Klinger V, Keksel C, Bonigut V,
Kiefer D, Caspers J, Walther J, Wos-Maganga M, Weickhardt S, Röhn
G, et al: Inhibition of the PI3K but not the MEK/ERK pathway
sensitizes human glioma cells to alkylating drugs. Cancer Cell Int.
18:692018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ahn KC, Choi JY, Kim JS, Hwang SG, Kim WJ,
Park JK and Um HD: ICAM-3 endows anticancer drug resistance against
microtubule-damaging agents via activation of the
ICAM-3-AKT/ERK-CREB-2 pathway and blockage of apoptosis. Biochem
Biophys Res Commun. 441:507–513. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Park EJ, Min KJ, Choi KS and Kwon TK:
Dicoumarol sensitizes renal cell carcinoma Caki cells to
TRAIL-induced apoptosis through down-regulation of Bcl-2, Mcl-1 and
c-FLIP in a NQO1-independent manner. Exp Cell Res. 323:144–154.
2014. View Article : Google Scholar : PubMed/NCBI
|
